DJIA 16,262.56 89.32 0.55%
NASDAQ 4,034.16 0.00 0.00%
S&P 500 1,842.98 12.37 0.68%
market minute promo

Isis Pharmaceuticals

NASDAQ: ISIS

32.99 -0.19 (-0.57%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $32.99 -0.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $33.23
Previous Close $33.18
Daily Range $30.80 - $34.22
52-Week Range $18.21 - $62.66
Market Cap $3.9B
P/E Ratio -61.64
Dividend (Yield) $0.00 (0.0%)
Volume 2,624,918
Average Daily Volume 2,155,806
Current FY EPS -$0.70

Sector

Healthcare

Industry

Drugs

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary Rss Feed

Which Themes in Biotech Today are Bankable?

RNAi is a new biotech technology investors need to watch.

Aegerion Shares Up on Study Initiation - Analyst Blog

PTC Therapeutics Looks Like A High-Risk Play On Rare Diseases

In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger

Isis Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ISIS

Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Geneti

Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)

Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

BBH, ALKS, BMRN, ISIS: Large Outflows Detected at ETF

Jim Cramer: Wait for the All-Clear

'Mad Money' Lightning Round: Stay Far Away From Boardwalk Partners

EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B

EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B Virus in an Animal Model of HBV

See More ISIS News...

ISIS's Top Competitors

ISIS $32.99 (-0.57%)
Current stock: ISIS
AMGN $115.00 (1.48%)
Current stock: AMGN
GILD $68.17 (2.07%)
Current stock: GILD
BIIB $285.49 (2.14%)
Current stock: BIIB